Southern California-based cardiac ablation technology developer Adagio Medical, Inc. closed a $42.5m series E equity financing on 12 November.
The new funds will support the ongoing investigational device exemption (IDE) trial of Adagio’s intelligent continuous lesion ablation cryoablation system (iCLAS) for treating persistent atrial fibrillation. The investment will...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?